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Abstract It has previously been shown that immune
complexes (IC) of a given biomarker with class M
immunoglobulins (IgM) provide better performances
compared to the unbound biomarker in a number of cancer
entities. In the present work, we investigated IC of IgM-Ab
as a potential biomarker for Alzheimer’s disease (AD).
Ab–IgM concentration has been measured in 75 plasma
samples from patients with AD, individuals with mild
cognitive impairment (MCI), and healthy age- and sex-
matched controls (HC). To characterize the fractions
associated with Ab, pooled plasma samples were subjected
to gel-ﬁltration analysis. Size-separated fractions were
analyzed for the presence of Ab using a sandwich ELISA
assay. A strong reactivity was observed in the high
molecular weight IgM ([500 kDa) and 150 kDa (IgG)
fractions indicating that blood Ab is strongly associated
with antibodies. Using an ELISA assay detecting Ab–IgM
complexes, we observed that high levels of Ab–IgMs were
detectable in HC and MCI patients; however, there was no
signiﬁcant difference to the AD group.
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Introduction
The earliest pathological events leading to Alzheimer’s
disease (AD) are estimated to occur 10–20 years before the
appearance of the ﬁrst cognitive changes in affected
patients (Price and Morris 1999; Yamaguchi et al. 2001).
Therefore, identiﬁcation of biomarkers predictive for AD
might allow screening for individuals who may beneﬁt
from preventive therapies before the development of cog-
nitive impairment. The Ab42 peptide is supposed to have a
central role in the pathogenesis of AD (Hardy and Selkoe
2002), and its measurement in the cerebrospinal ﬂuid
(CSF) became nowadays a routine diagnostic procedure
with 75–95% sensitivity and speciﬁcity (Blennow 2004;
Jensen et al. 1999; Lewczuk et al. 2004). Unfortunately,
CSF and blood levels of Ab do not correlate, neither in AD
patients (Mehta et al. 2001) nor in healthy controls (Mehta
and Pirttila 2005). On the other side, it has been also shown
that there is a correlation between CSF and plasma levels
of Ab40 and Ab42 in healthy individuals, whereas no such
correlation could be seen for AD or MCI cases (Giedraitis
et al. 2007).
Studies on plasma Ab levels have shown contradictory
results, ranging from increased Ab40 and decreased Ab42
in AD patients compared to healthy controls (Xu and
Gaskin 2008), no differences (Fukumoto et al. 2003;
Vanderstichele et al. 2000) or increased Ab42 in AD
patients (Matsubara et al. 1999). The different ﬁndings in
these studies may be due to differences in study designs,
including variations in age and disease severity of included
subjects. A longitudinal study showed that plasma Ab40
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DOI 10.1007/s00702-009-0224-yand Ab42 levels measured at age 70 years were not sig-
niﬁcantly associated with incident AD (Sundelof et al.
2008). All of the studies though, have shown substantial
overlap in plasma Ab40 and Ab42 levels between patients
and controls, thus limiting the diagnostic value of plasma
Ab assessment. Although the signiﬁcance of Ab for diag-
nosing Alzheimer’s disease is controversial, high plasma
concentrations of Ab40 and low plasma concentrations of
Ab42 indicate an increased risk of dementia (reviewed in
Kawarabayashi and Shoji 2008). Nonetheless, analysis of
plasma instead of CSF would be highly desirable because
of its better accessibility and less invasive sampling pro-
cedure. Plasma Ab levels are commonly quantiﬁed with
enzyme-linked immunoabsorbent assays (ELISA) using
antibodies against a variety of Ab epitopes (for example
Mehta et al. 2000; Suzuki et al. 1994). Quantiﬁcation of Ab
in blood is technically difﬁcult and limited by the fact that
most of it is bound to blood components, including lipids
serum albumin, a2-macroglobulin, immunoglobulins,
apolipoprotein J, transthyritin, apoferritin, as well as
complement components C1q and C3 (Biere et al. 1996;
Kuo et al. 2000).
Besides the detection of biochemical AD markers,
autoimmune responses to molecules speciﬁc to AD
pathology have become a current research focus (Gruden
et al. 2004; Nath et al. 2003). There seems to be a reduction
in the magnitude of lymphocyte stimulation by APP in AD
patients (Trieb et al. 1996), and naturally occurring anti-Ab
antibodies seem to be present in sera and CSF of AD
patients and healthy controls (Du et al. 2001). However,
whether autoimmunity plays a direct role in the patho-
genesis of AD is still open to debate (McGeer and McGeer
2001; Singh 1997; Tarkowski et al. 2003).
In the present study, the level of circulating immune
complexes (ICs) between Ab and class M immunoglobu-
lins (IgM) has been investigated, because ICs have been
shown to be relevant biomarkers for different types of
cancers (Beneduce et al. 2005, 2006; Castaldi et al. 2005),




Plasma samples (stored at -70C) from 30 out-patients
with mild to moderate AD, 15 patients with mild cognitive
impairment (MCI) and 30 healthy controls (HC) were
analyzed. The patients were recruited at the Memory Clinic
at the Department of Geriatrics, Uppsala University Hos-
pital. All AD patients were diagnosed according to DSM
IV (American Psychiatric Association 2000) and NINCDS-
ADRDA (McKhann et al. 1984). The MCI patients met the
Petersen criteria (Winblad et al. 2004) for MCI.
Gel ﬁltration
Plasma samples from ﬁve AD patients and ﬁve healthy
controls showing high reactivity to Ab–IgM immune
complexes in a preliminary assay were grouped and ana-
lyzed by gel-ﬁltration HPLC. 500 ll of pooled samples
were analyzed using a gel-ﬁltration column Superdex 200
10/300 GL (GE Healthcare, Freiburg, Germany) on an
ACTA Basic system (GE Healthcare, Freiburg, Germany).
The elution was carried out in PBS at a ﬂow rate of 1 ml
per minute, and sample absorbance was monitored at
280 nm. Fractions were collected every 30 s, immunore-
activity was tested by ELISA and the fractions corre-
sponding to the highest immunoreactivity were pooled and
used as reference standard. Before running the samples, a
calibration run was carried out according to the manufac-
turer’s instructions.
ELISA assay to detect Ab
The Ab level in gel-ﬁltration fractions was determined as
follows: 96-well ELISA plates were coated with 50 ll per
well of 1 lg/ml of mouse anti-human Ab antibody directed
against residues 17-24 (4G8, Signet Laboratories, Dedham,
MA, USA) in PBS at 4C overnight and then blocked for
2 h with 3% BSA in PBS at 37C. After blocking, 50 llo f
gel-ﬁltration fractions in PBS containing 1% BSA and
0.05% Tween 20 (PBS-B-T) were incubated for 1.5 h at
37C. The wells were then washed with PBS containing
0.05% Tween 20 and incubated with 50 ll of rabbit
polyclonal anti-Ab 692 (generous gift from Gerd Mult-
haup, Free University of Berlin) at a 1:1,000 dilution in
PBS-B-T for 1.5 h at 37C. Ab was revealed using per-
oxidase-conjugated goat anti-rabbit IgG (Dako, Glostrup,
Denmark) in a 1:1,000 dilution in PBS-B-T and developed
with TMB (Pierce manufacturing, Appleton, IL, USA) and
hydrogen peroxide as substrate. The results of Ab deter-
mination in the gel-ﬁltration fractions were reported in
optical density.
ELISA assay to detect Ab–IgM immune complexes
96-well ELISA plates were coated with 50 lL per well of
1 lg/mL 4G8 antibody (Signet Laboratories, Dedham,
MA, USA) in PBS at 4C overnight and then blocked for
2 h with 3% BSA in PBS. After blocking, 50 ll of serially
diluted reference standard or samples in PBS-B-T were
incubated for 1.5 h at 37C. The Ab–IgM complex was
revealed using peroxidase-conjugated anti-human IgM
(Sigma-Aldrich, Munich, Germany) at a dilution of 1:3,000
914 A. Marcello et al.
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oxide as the substrate. Ab–IgM IC levels in the plasma
were expressed in arbitrary units/ml (AU/ml) by using gel-
ﬁltration-puriﬁed Ab–IgM reference standards to design a
calibration curve, where the undiluted standard was
assigned 1,000 AU/ml; concentration was determined by
interpolation of samples absorbance on the calibration
curve. The linear range of the assay was between 3.9 and
62.5 AU/ml. The samples with values above 62.5 AU/ml
were further diluted and re-measured. The assay was
standardized and its analytical performance evaluated:
inter- and intra-assay coefﬁcient of variation (CV) was less
than 10%. Ab–IgM cut-off was selected as the best com-
bination of speciﬁcity and sensitivity according to the
receiver-operating characteristic (ROC) curve.
Western blot
Gel-ﬁltration fractions corresponding to 280 nm absor-
bance peaks were separated on a 4–12% variogel (Anamed,
Groß-Bieberau, Germany) and then transferred to a nitro-
cellulose membrane. The membrane was heated in PBS in
a microwave for 5 min and then blocked in 10% non-fat
dry milk in TBS containing 0.05% Tween (TBS-T) for 1 h
at room temperature. Blots were then incubated with per-
oxidase-conjugated goat anti-human IgM (Sigma-Aldrich)
at 1:1,000 in TBS-T for 2 h or, alternatively, with a pri-
mary antibody directed against Ab residues 4-10 (W0-2,
The Genetics Company, Switzerland) overnight at 4C and
secondary peroxidase-conjugated antibodies for 2 h at
room temperature. Protein bands were revealed using
chemiluminescence solution and peroxide hydrogen as
substrates on a Curix60 developing machine (Agfa-Gevaert
N.V., Mortsel, Belgium).
Data analysis
All biomarker values were expressed as mean val-
ues ± standard deviation. Differences between the groups
were determined by ANOVA followed by Student t tests.
The diagnostic powers were determined by ROC curve
analysis. Chi-square test on independence was used to
analyze, if the gender distribution was signiﬁcantly dif-
ferent between the three groups and if there is a difference
between the two patient groups in relation to the number of
family members with dementia. All analyses were per-
formed using GraphPad Prism (GraphPad software, Inc.,
La Jolla, CA, USA and SPSS 16 for Windows). Signiﬁ-
cance level was a = 0.05. All tests were two-tailed.
Results
There were no signiﬁcant age differences between the three
groups [Alzheimer patients (AD), MCI and healthy con-
trols] (F = 0.3, df = 2, 72; P = 0.74). Patients with MCI
diagnosis were not signiﬁcantly older at onset of the dis-
ease than AD patients (F = 2.3, df = 1, 42; P = 0.13). As
expected, the mean MMSE score was higher in MCI
compared to AD patients (F = 44.3, df = 1, 40;
P\0.0005). Gender distribution was not signiﬁcantly
different between the three groups (Chi
2 = 1.2, df = 2;
P = 0.55) and the proportion of family members with
dementia did not differ signiﬁcantly between the two
patients groups (Chi
2 = 0.8, df = 1; P = 0.38) (Table 1).
In order to identify circulating Ab–IgM complexes,
plasma samples from ten individuals were pooled and
analyzed by gel ﬁltration. Fractions collected from the
column were tested for the presence of generic Ab and Ab–
IgM complexes using ELISA assays. A strong immunore-
activity against Ab was observed in the fraction eluting at
high molecular weight ([500 kDa) (Fig. 1a). In the same
fraction high reactivity for ICs of Ab with IgM was also
found, thus providing the ﬁrst evidence of the occurrence of
circulating Ab–IgM complexes (Fig. 2c). Reactivity for
generic Ab was also found in the fractions eluting at
150 kDa (IgG fraction) and at low molecular weight (not
shown). Reactivity against the monomeric form of Ab has
been found in all fractions, conﬁrming previous observa-
tions (Kuo et al. 2000). The fractions contained components
Table 1 Demographic data of the studied groups
AD MCI HC Chi
2 df P
Gender (male, female) M: 12, F: 18 M: 8, F: 7 M:11, F: 19 1.2 2 0.55
Dementia in family Yes: 16, no: 12 Yes: 6, no: 8 0.8 1 0.38
n m ± SD n m ± SD n m ± SD Fd fP
Age (years) 30 72.3 ± 6.7 15 73.7 ± 4.3 30 72.5 ± 5.2 0.3 2, 72 0.74
Age at onset (years) 30 67.9 ± 7.9 14 71.4 ± 4.9 2.3 1, 42 0.13
MMSE (at screening) 27 17.3 ± 6.1 15 27.9 ± 1.3 44.3 1, 40 \0.0005
AD Alzheimer’s disease, MCI mild cognitive impaired individuals, HC healthy controls, m mean, SD standard deviation, Chi
2 Chi-square
statistic, F F-statistic, df degrees of freedom, P probability, M male, F female
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123migrating at the expected molecular weight for reduced IgM
that were stained by antihuman IgM antibodies (Fig. 1b).
To assess the relevance of these ﬁndings, plasma sam-
ples from 75 patients with AD, MCI, and from healthy
donors were analyzed for the presence of Ab–IgM ICs.
Serial dilutions of the gel ﬁltration-puriﬁed IC fraction
have been used to draw a reference calibration curve.
By interpolation with the standard curve, Ab–IgM IC
concentration in the plasma samples has been expressed in
arbitrary units (AU)/ml. According to ANOVA test, no
signiﬁcant differences among the three diagnostic groups
were observed (Student t test P value AD vs. HC = 0.18,
AD vs. MCI = 0.61, MCI vs. HC = 0.10) (Fig. 3).
ROC curve analysis showed that speciﬁcity was only
46.67% when sensitivity was set at 80%, and by setting
speciﬁcity above 80%, sensitivity was 26.67% (Table 2).
Discussion
The aim of the present study was to analyze the serological
proﬁle of samples from AD and MCI patients, and healthy
controls, regarding the levels of Ab–IgM complexes, and to
evaluate a possible correlation between the immunological
proﬁles of individuals with AD. Immune complexes, in
fact, have recently been proven to correlate better than
unbound biomarkers with pathology in different cancer
entities (Beneduce et al. 2005, 2007, 2008; Castaldi et al.
2005), which are characterized by an over- or mis-pro-
duction of an endogenous protein. At present, only CSF
Ab42 levels is a well established Ab-related AD biomarker
with high sensitivity and speciﬁcity (Andreasen et al. 2001;
Galasko et al. 1998; Kanai et al. 1998; Lewczuk et al.
2004; Tapiola et al. 2000). Unfortunately, there seems to be
no correlation between CSF and blood Ab level, as shown
by several groups (Matsumoto et al. 2007; Mehta et al.
2000, 2001; Vanderstichele et al. 2000). A longitudinal
study showed that CSF Ab42 decreases within 12 months
signiﬁcantly in AD patients, while Tau and Phospho-Tau
did not (Kessler et al. 2008). Although much better for
clinical practice, blood-based Ab levels are controversially
discussed as a useful biomarker for AD. Studies have
shown a decreased level of Ab in AD subjects (Pesaresi
et al. 2006; Xu and Gaskin 2008), while others showed an
Fig. 1 a Gel-ﬁltration HPLC of
pooled plasma samples. Proteins
are separated according to their
molecular weight, with the
larger proteins eluting ﬁrst.
Total protein concentration of
each fraction was measured at
280 nm (gray line). The
characteristic peaks were as
follows: empty volume with a
MW[500 kDa (IgMs), IgGs
with a MW of *150 kDa, and
the albumin peak at *66 kDa.
A direct ELISA performed on
each fraction to measure the
quantity of generic Ab
(diamonds) shows that most of
Ab elutes in the empty volume
and IgG fractions suggesting
that Ab in the blood is strongly
associated with antibodies.
b Western blot against Ab in the
empty volume (IgM) fraction
and IgM showing the presence
of Ab in the IgM fraction
916 A. Marcello et al.
123increase of Ab concentration in the plasma of AD patients
(Kosaka et al. 1997; Matsubara et al. 1999), or no statistical
differences (Fukumoto et al. 2003; Tamaoka et al. 1996).
The same inconsistency emerged from a series of pro-
spective studies, in which a higher risk for developing AD
has been associated both with higher baseline plasma Ab42
concentration (Pomara et al. 2005) or higher Ab40 with no
effect on Ab42 (van Oijen et al. 2006). Finally, Graff-
Radford et al. (2007) linked a high risk for developing AD
to a lower Ab42/40 ratio. Plasma anti-Ab autoantibody
concentration has also been investigated by several groups.
Titers of anti-Ab42 autoantibodies were reported to be
lower in AD patients compared to healthy individuals (Du
et al. 2001; Weksler et al. 2002), or higher in AD patients
(Nath et al. 2003). One study reported no correlation
between autoantibodies titers and plasma Ab40 or 42 levels
(Hyman et al. 2001).
The initial goal of this study was to characterize the
occurrence of ICs of Ab in the plasma of AD and MCI
patients and HC, as seen with many cancer biomarkers. It is
well known that IgM complexes are in equilibrium in blood
with the unbound respective antigen and are used as reli-
able blood biomarkers for diagnosis of different cancer
entities. It would make sense that the same equilibrium
holds true for any IgM complex in blood. Already estab-
lished immune complexes as biomarkers include: PSA–
IgM for prostate cancer (Beneduce et al. 2007), carcino-
embryonic antigen–IgM for colorectal cancer (Castaldi
et al. 2005) alpha fetoprotein–IgM and squamous cell
carcinoma antigen-IgM for liver cancer (Beneduce et al.
2004, 2005). Moreover, IgM immune complexes have also
been shown to be uncorrelated with basal IgM levels
(Beneduce 2008). Nydegger (2007) discussed in a review
article biochemical properties of immune complexes in
general, their formation and their equilibrium state, stating
that immune complex interaction is extremely high com-
pared to other biochemical interactions.
Plasma samples from 30 AD patients, 15 MCI patients,
and 30 age- and sex-matched HC have been analyzed to
determine the levels of circulating Ab–IgM ICs. After gel-
ﬁltration and size fractionation, Ab was primarily found to
be associated with the IgM and the IgG fractions using an
ELISA. This is the ﬁrst characterization of circulating Ab–
IgM complexes in AD. The Ab–IgM assay did not show
any signiﬁcant difference among the three groups, in
contrast with previous ﬁndings (Gruden et al. 2007),
Fig. 2 a Sandwich ELISA. 96-well titer plates are coated with anti-
Ab (4G8). After incubation with plasma samples, the wells are
washed and incubated with an anti-IgM heavy chain antibody
conjugated with HRP. Signal of bound molecules is therefore only
produced by complexes of both IgM and antigen. b Calibration curve
obtained by serial dilutions of the IgM fraction. c Ab-IgM (diamonds)
immune complexes in the fractions derived from gel-ﬁltration HPLC
compared to total protein concentration (solid line)
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immunity in AD, IC levels cannot be used as a diagnostic
marker. It should be noted, however, that variability of IC
level was high within the groups. This high variance
leading to an overlap between AD patients and healthy
controls might be partly due to biological variability.
Consensus criteria for a suitable biomarker (Trojanowski
et al. 1998) for AD were however not met.
On the other hand, the presence of circulating ICs
against neuronal antigens supports the notion that autoim-
mune-mediated processes may be involved in neurode-
generative disorders. Further investigations are needed to
elucidate the pathophysiological role of these complexes
and the signiﬁcance of autoantibodies in AD in general.
Whether their role is neuroprotective or neurotoxic is still
unknown. They may be seen both as a possible protective
factor for AD, or as a risk factor in case of an unbalanced
level. In any case, autoimmunity-driven homeostasis is a
natural process and its understanding may be useful in both
diagnosing and treating AD; there are evidences for a
therapeutic use of anti-Ab antibodies as it is being shown
by current experimental immunotherapeutic approaches.
Hock et al. (2003) showed that active immunization against
aggregated Ab42 led to a slower cognitive decline in a
dose-dependent fashion; patients generating a higher titer
of anti-Ab antibodies performed better in cognitive test
than patients who did not respond to the immunization
protocol. The increase in antibody titer did not correspond
to a decrease in Ab blood levels. In contrast, signiﬁcant
changes were observed in serum and CSF of patients with
AD after treatment with intravenous Ab IgGs (Dodel et al.
2002).
The levels of Ab autoantibodies of the IgG class for
monitoring the effect of passive or active immunization in
AD have already been evaluated by recent studies. It is
speculative to discuss a possible role of Ab–IgM levels as a
predictive indicator of immunotherapy efﬁcacy. A possible
hypothesis includes that they serve as a ‘‘buffering system’’
to keep free potential toxic endogenous peptides and pro-
teins under homeostatic control and lead to their clearance
(Gruden et al. 2007). Previous studies have shown the
presence of anti-Ab autoantibodies (Xu and Gaskin 1997)
and circulating IC of Ab and IgGs of different classes
(Gruden et al. 2004). APP transgenic mice injected intra-
venously with monoclonal anti-Ab antibody showed a
rapid and massive increase of CNS-derived Ab in the
plasma suggesting that antibodies may participate in Ab
clearance from the brain (DeMattos et al. 2001). However,
whether this immune activity is defensive or toxic is still a
matter of debate (Geylis et al. 2005; Nath et al. 2003;
Woulfe et al. 2002). It will be interesting to evaluate in
future studies possible relationships of Ab-IC levels with
the clinical development of MCI patients, and with AD
patients’ response to immune therapies.
Acknowledgments The excellent technical help of Petra Tucholla
is gratefully acknowledged. Financial support was provided by the
European Commission, Marie Curie Early Stage Training, MEST-
Fig. 3 Analysis of Ab–IgM immune complexes. a Levels of Ab–IgM
immune complexes in the different diagnostic groups. b The
comparison of the mean values do not show any signiﬁcant
difference. c ROC curve analysis shows a certain difference in the
distribution of the immune complexes plasma concentration between
AD and HC groups, which however was not signiﬁcant
Table 2 Comparison of speciﬁcity, sensitivity, positive predictive
value (PPV = true positive (TP)/TP ? false positive), negative pre-
dictive value (NPV = true negative (TN)/TN ? false negative) of
Ab-IgM comparing AD patients with the healthy control (HC) group
Biomarker Cut-off
(AU/mL)
Sensitivity Speciﬁcity PPV NPV
Ab-IgM \1926 80% (24/30) 46.67% (16/30) 60% 70%
\648.5 26.67% (8/30) 80% (6/30) 57% 52%
918 A. Marcello et al.
123CT-2005-020013 (NEURAD), International Alzheimer Ph.D. Grad-
uate School.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
American Psychiatric Association (2000) Diagnostic and statistical
manual of mental disorders—DSM-IV, 4th edn. American
Psychiatric Association, Washington
Andreasen N, Minthon L, Davidsson P, Vanmechelen E et al (2001)
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers
for Alzheimer disease in clinical practice. Arch Neurol
58(3):373–379
Beneduce L, Castaldi F, Marino M, Tono N et al (2004) Improvement
of liver cancer detection with simultaneous assessment of
circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM
complexes. Int J Biol Markers 19(2):155–159
Beneduce L, Castaldi F, Marino M, Quarta S et al (2005) Squamous
cell carcinoma antigen-immunoglobulin M complexes as novel
biomarkers for hepatocellular carcinoma. Cancer 103(12):2558–
2565
Beneduce L, Prayer-Galetti T, Giustinian AM, Gallotta A et al (2007)
Detection of prostate-speciﬁc antigen coupled to immunoglob-
ulin M in prostate cancer patients. Cancer Detect Prev
31(5):402–407
Beneduce L, Pesce G, Gallotta A, Zampieri F et al (2008) Tumour-
speciﬁc induction of immune complexes: DCP-IgM in hepato-
cellular carcinoma. Eur J Clin Invest 38(8):571–577
Biere AL, Ostaszewski B, Stimson ER, Hyman BT et al (1996)
Amyloid beta-peptide is transported on lipoproteins and albumin
in human plasma. J Biol Chem 271(51):32916–32922
Blennow K (2004) Cerebrospinal ﬂuid protein biomarkers for
Alzheimer’s disease. NeuroRx 1(2):213–225
Castaldi F, Marino M, Beneduce L, Belluco C et al (2005a) Detection
of circulating CEA-IgM complexes in early stage colorectal
cancer. Int J Biol Markers 20(4):204–208
Castaldi F, Marino M, Beneduce L, Belluco C et al (2005b) Detection
of circulating CEA-IgM complexes in early stage colorectal
cancer Squamous cell carcinoma antigen-immunoglobulin M
complexes as novel biomarkers for hepatocellular carcinoma. Int
J Biol Markers 20(4):204–208
DeMattos RB, Bales KR, Cummins DJ, Dodart JC et al (2001)
Peripheral anti-A beta antibody alters CNS and plasma A beta
clearance and decreases brain A beta burden in a mouse model of
Alzheimer’s disease. Proc Natl Acad Sci USA 98(15):8850–
8855
Dodel R, Hampel H, Depboylu C, Lin S et al (2002) Human
antibodies against amyloid beta peptide: a potential treatment for
Alzheimer’s disease. Ann Neurol 52(2):253–256
Du Y, Dodel R, Hampel H, Buerger K et al (2001) Reduced levels of
amyloid beta-peptide antibody in Alzheimer disease. Neurology
57(5):801–805
Fukumoto H, Tennis M, Locascio JJ, Hyman BT et al (2003) Age but
not diagnosis is the main predictor of plasma amyloid beta-
protein levels. Arch Neurol 60(7):958–964
Galasko D, Chang L, Motter R, Clark CM et al (1998) High
cerebrospinal ﬂuid tau and low amyloid beta42 levels in the
clinical diagnosis of Alzheimer disease and relation to apolipo-
protein E genotype. Arch Neurol 55(7):937–945
Geylis V, Kourilov V, Meiner Z, Nennesmo I et al (2005) Human
monoclonal antibodies against amyloid-beta from healthy adults.
Neurobiol Aging 26(5):597–606
Giedraitis V, Sundelof J, Irizarry MC, Garevik N et al (2007) The
normal equilibrium between CSF and plasma amyloid beta
levels is disrupted in Alzheimer’s disease. Neurosci Lett
427(3):127–131
Graff-Radford NR, Crook JE, Lucas J, Boeve BF et al (2007)
Association of low plasma Abeta42/Abeta40 ratios with
increased imminent risk for mild cognitive impairment and
Alzheimer disease. Arch Neurol 64(3):354–362
Gruden MA, Davudova TB, Malisauskas M, Zamotin VV et al (2004)
Autoimmune responses to amyloid structures of Abeta(25–35)
peptide and human lysozyme in the serum of patients with
progressive Alzheimer’s disease. Dement Geriatr Cogn Disord
18(2):165–171
Gruden MA, Davidova TB, Malisauskas M, Sewell RD et al (2007)
Differential neuroimmune markers to the onset of Alzheimer’s
disease neurodegeneration and dementia: autoantibodies to
Abeta(25–35) oligomers, S100b and neurotransmitters. J Neu-
roimmunol 186(1–2):181–192
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s
disease: progress and problems on the road to therapeutics.
Science 297(5580):353–356
Hock C, Konietzko U, Streffer JR, Tracy J et al (2003) Antibodies
against beta-amyloid slow cognitive decline in Alzheimer’s
disease. Neuron 38(4):547–554
Hyman BT, Smith C, Buldyrev I, Whelan C et al (2001) Autoanti-
bodies to amyloid-beta and Alzheimer’s disease. Ann Neurol
49(6):808–810
Jensen M, Schroder J, Blomberg M, Engvall B et al (1999)
Cerebrospinal ﬂuid A beta42 is increased early in sporadic
Alzheimer’s disease and declines with disease progression. Ann
Neurol 45(4):504–511
Kanai M, Matsubara E, Isoe K, Urakami K et al (1998) Longitudinal
study of cerebrospinal ﬂuid levels of tau, A beta1-40, and A
beta1-42(43) in Alzheimer’s disease: a study in Japan. Ann
Neurol 44(1):17–26
Kawarabayashi T, Shoji M (2008) Plasma biomarkers of Alzheimer’s
disease. Curr Opin Psychiatry 21(3):260–267
Kessler H, Pajonk FG, Bach D, Schneider-Axmann T et al (2008)
Effect of copper intake on CSF parameters in patients with mild
Alzheimer’s disease: a pilot phase 2 clinical trial. J Neural
Transm 115(12):1651–1659
Kosaka T, Imagawa M, Seki K, Arai H et al (1997) The beta APP717
Alzheimer mutation increases the percentage of plasma amyloid-
beta protein ending at A beta42(43). Neurology 48(3):741–745
Kuo YM, Kokjohn TA, Kalback W, Luehrs D et al (2000a) Amyloid-
beta peptides interact with plasma proteins and erythrocytes:
implications for their quantitation in plasma. Biochem Biophys
Res Commun 268(3):750–756
Kuo YM, Kokjohn TA, Kalback W, Luehrs D et al (2000b) Amyloid-
beta peptides interact with plasma proteins and erythrocytes:
implications for their quantitation in plasma. Biochem Biophys
Res Commun 268(3):750–756
Lewczuk P, Esselmann H, Otto M, Maler JM et al (2004)
Neurochemical diagnosis of Alzheimer’s dementia by CSF
Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol Aging
25(3):273–281
Matsubara E, Ghiso J, Frangione B, Amari M et al (1999)
Lipoprotein-free amyloidogenic peptides in plasma are elevated
in patients with sporadic Alzheimer’s disease and Down’s
syndrome. Ann Neurol 45(4):537–541
Matsumoto Y, Yanase D, Noguchi-Shinohara M, Ono K et al (2007)
Blood-brain barrier permeability correlates with medial temporal
lobe atrophy but not with amyloid-beta protein transport across
Circulating immune complexes of Ab and IgM in plasma 919
123the blood–brain barrier in Alzheimer’s disease. Dement Geriatr
Cogn Disord 23(4):241–245
McGeer PL, McGeer EG (2001) Inﬂammation, autotoxicity and
Alzheimer disease. Neurobiol Aging 22(6):799–809
McKhann G, Drachman D, Folstein M, Katzman R et al (1984)
Clinical diagnosis of Alzheimer’s disease: report of the NIN-
CDS-ADRDA Work Group under the auspices of Department of
Health and Human Services Task Force on Alzheimer’s Disease.
Neurology 34(7):939–944
Mehta PD, Pirttila T (2005) Increased cerebrospinal ﬂuid A beta38/A
beta42 ratio in Alzheimer disease. Neurodegener Dis 2(5):242–
245
Mehta PD, Pirttila T, Mehta SP, Sersen EA et al (2000) Plasma and
cerebrospinal ﬂuid levels of amyloid beta proteins 1-40 and 1-42
in Alzheimer disease. Arch Neurol 57(1):100–105
Mehta PD, Pirttila T, Patrick BA, Barshatzky M et al (2001) Amyloid
beta protein 1-40 and 1-42 levels in matched cerebrospinal ﬂuid
and plasma from patients with Alzheimer disease. Neurosci Lett
304(1–2):102–106
Nath A, Hall E, Tuzova M, Dobbs M et al (2003) Autoantibodies to
amyloid beta-peptide (Abeta) are increased in Alzheimer’s
disease patients and Abeta antibodies can enhance Abeta
neurotoxicity: implications for disease pathogenesis and vaccine
development. Neuromolecular Med 3(1):29–39
Nydegger UE (2007) Immune complex pathophysiology. Ann N Y
Acad Sci 1109:66–83
Pesaresi M, Lovati C, Bertora P, Mailland E et al (2006) Plasma
levels of beta-amyloid (1-42) in Alzheimer’s disease and mild
cognitive impairment. Neurobiol Aging 27(6):904–905
Pomara N, Willoughby LM, Sidtis JJ, Mehta PD (2005) Selective
reductions in plasma Abeta 1-42 in healthy elderly subjects
during longitudinal follow-up: a preliminary report. Am J Geriatr
Psychiatry 13(10):914–917
Price JL, Morris JC (1999) Tangles and plaques in nondemented
aging and ‘‘preclinical’’ Alzheimer’s disease. Ann Neurol
45(3):358–368
Singh VK (1997) Neuroautoimmunity: pathogenic implications for
Alzheimer’s disease. Gerontology 43(1–2):79–94
Sundelof J, Giedraitis V, Irizarry MC, Sundstrom J et al (2008)
Plasma beta amyloid and the risk of Alzheimer disease and
dementia in elderly men: a prospective, population-based cohort
study. Arch Neurol 65(2):256–263
Suzuki N, Cheung TT, Cai X-D, Odaka A et al (1994) An increased
percentage of long amyloid b protein is secreated by familial
amyloid b protein precursor (bAPP717) mutants. Science
264:1336–1340
Tamaoka A, Fukushima T, Sawamura N, Ishikawa K et al (1996)
Amyloid beta protein in plasma from patients with sporadic
Alzheimer’s disease. J Neurol Sci 141(1–2):65–68
Tapiola T, Pirttila T, Mehta PD, Alafuzofff I et al (2000) Relationship
between apoE genotype and CSF beta-amyloid (1-42) and tau in
patients with probable and deﬁnite Alzheimer’s disease. Neuro-
biol Aging 21(5):735–740
Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003)
Intrathecal inﬂammation precedes development of Alzheimer’s
disease. J Neurol Neurosurg Psychiatry 74(9):1200–1205
Trieb K, Ransmayr G, Sgonc R, Lassmann H et al (1996) APP
peptides stimulate lymphocyte proliferation in normals, but not
in patients with Alzheimer’s disease. Neurobiol Aging 17(4):
541–547
Trojanowski JQ, Growdon JH (1998) A new consensus report on
biomarkers for the early antemortem diagnosis of Alzheimer
disease: current status, relevance to drug discovery, and recom-
mendations for future research. J Neuropathol Exp Neurol
57(6):643–644
van Oijen M, Hofman A, Soares HD, Koudstaal PJ et al (2006)
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a
prospective case–cohort study. Lancet Neurol 5(8):655–660
Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P et al
(2000) Standardization of measurement of beta-amyloid(1-42) in
cerebrospinal ﬂuid and plasma. Amyloid 7(4):245–258
Weksler ME, Relkin N, Turkenich R, LaRusse S et al (2002) Patients
with Alzheimer disease have lower levels of serum anti-amyloid
peptide antibodies than healthy elderly individuals. Exp Gerontol
37(7):943–948
Winblad B, Palmer K, Kivipelto M, Jelic V et al (2004) Mild
cognitive impairment—beyond controversies, towards a consen-
sus: report of the International Working Group on Mild
Cognitive Impairment. J Intern Med 256(3):240–246
Woulfe JM, Duke R, Middeldorp JM, Stevens S et al (2002) Absence
of elevated anti-alpha-synuclein and anti-EBV latent membrane
protein antibodies in PD. Neurology 58(9):1435–1436
Xu S, Gaskin F (1997) Increased incidence of anti-beta-amyloid
autoantibodies secreted by Epstein-Barr virus transformed B cell
lines from patients with Alzheimer’s disease. Mech Ageing Dev
94(1–3):213–222
Xu W, Kawarabayashi T, Matsubara E, Deguchi K et al (2008)
Plasma antibodies to Abeta40 and Abeta42 in patients with
Alzheimer’s disease and normal controls. Brain Res 1219:169–
179
Yamaguchi H, Sugihara S, Ogawa A, Oshima N et al (2001)
Alzheimer beta amyloid deposition enhanced by apoE epsilon4
gene precedes neuroﬁbrillary pathology in the frontal association
cortex of nondemented senior subjects. J Neuropathol Exp
Neurol 60(7):731–739
920 A. Marcello et al.
123